



Nodus Oncology announces the appointment of Thomas Wirth as chief business officer

Edinburgh, UK – 27/07/23 – Nodus Oncology, an emerging biotech company which is focused on developing first and best-in-class molecules inhibiting novel DDR targets, is pleased to announce the appointment of Dr Thomas Wirth as Chief Business Officer.

“The appointment of Thomas is a great addition to the Nodus team” said Ian Waddell, CEO of Nodus Oncology. Thomas is a qualified and result-driven professional with an interdisciplinary background and strong business acumen. He has extensive experience in establishing companies, working closely with investors, Boards of Directors, and executive leadership. As a Founder and formerly CSO of Aurealis Therapeutics, he has spearheaded the Research and Development of a topical cell therapy for diabetic foot ulcers. He also chaired the Board of Celloryx AG, an oncology-focused gene therapy company. Additional career highlights include working as a Research Director at Ark Therapeutics, wherein he established preclinical proof-of-concept for two oncological gene therapy products as well as working 12 years as a Senior Research Scientist for the University of Eastern Finland, where he conducted research on the immunological environment of brain tumours and was granted a docentship based on his scientific achievements. Thomas has a history of defining roadmaps and translating innovative ideas into strategic products. He is well-versed in building and maintaining strong relationships with internal and external stakeholders at all levels, leading and motivating teams to bring new and effective treatments to patients.

About Nodus Oncology

Nodus Oncology is a biotech company developing first and best-in-class molecules focused on the DNA damage response (DDR) in patient sub-groups where molecular vulnerabilities exist. Founded by Cumulus Oncology, which contributes capital and oncology discovery and development expertise to the creation of new biotech companies, Nodus has received seed investment from both Cumulus Oncology and additional investors. www.nodusoncology.com